Journal of Biomedical Engineering and Medical Devices
ISSN: 2475-7586
OPEN ACCESS Freely available online
Editorial

A View Point on Effectiveness of COVID-19 Vaccines

Dalvinder Singh Grewal*

Department of Business Executive and Prolific Writer, Desh Bhagagat University, Punjab, India

EDITORIAL

There are two lobbies among the vaccines about the treatment of COVID-19. One set of scientist recommend these vaccines to be very useful and another have doubts about their effectiveness. Some say that these vaccines are not a sure treatment and ultimately affect genetic structure. Those in favour of vaccines have varying claims about the effective ness of these vaccines. The claims of effectiveness of various vaccines range from 100% of Russia Pfizer (99.4%) Oxford-AstraZeneca of England, Covishield and Covaxin of India to Spuntnik V of 92% to protect from COVID-19. These vaccines require two doses with a gap of 28 days to develop antibodies against the COVID-19 virus. The results of first vaccines of Covishield and Covaxin administered in India show a few of causalities while the second doze is yet to be administered. However, the first doze confirms that they are not hundred per cent effective. In a study in England, almost 100% of study participants aged 18–55 years had developed potent antibodies against the virus 57 days after receiving a single low dose of the vaccine. The team tested the antibodies' response to samples of the virus's spike protein. Receptor Binding Domain (RBD) is the different versions of a region carried by each sample protein. These recognize host cells. These are also a major target for antibodies. Proteins infection or coronavirus RNA stay in the digestive-tract lining for months causing rapid declining of the superimposed immunity to the virus. A research team of Rockefeller University NY found that the levels of antibodies against the coronavirus's spike protein declined over six months.

A study on a vaccine by USA revealed the vaccine to be 94% effective at preventing symptomatic COVID-19, and preliminary analysis, the author hint that only 1 dose of the vaccine may also provide some defence against asymptomatic disease. All 30 trial participants who developed severe COVID-19 were within the placebo arm. About 1/2 volunteers who received the vaccine experienced side effects like headaches after their second dose. But serious side effects were rare and occurred as frequently within the placebo group as within the vaccinated group. A Study by Alexander Misharin at North-western University in Evanston, Illinois which examined fluid from the lungs of 88 people with severe pneumonia caused by SARS-CoV-2 infection with most of these individuals having high numbers of a certain type of T cell, a class of immune cells, in their lungs. The researchers found that nearly 70% of alveolar macrophages, a type of immune cell that is located in the tiny air sacs of the lungs, contained SARS-CoV-2. The cells containing the virus showed relatively high imprints of genes that are involved in inflammation. As the virus reaches the lungs, it may infect macrophages, responding by producing inflammatory molecules that attract T cells. T cells, in turn, produce a protein that stimulates macrophages to create more inflammatory molecules. This persistent lung inflammation could lead to a number of the life-threatening consequences of SARS-CoV-2 infection. Jesse Bloom at the Fred Hutchinson Cancer Research Centre in Seattle, Washington, and his colleagues studied antibodies against SARS-CoV-2 isolated from the blood serum of individuals who had recovered from COVID-19. Pathogens normally attack antibodies. Occasionally, rogue antibodies capture bodily components like immune cells. Tying of autoantibodies is the new analysis on the growing body against the poor outcomes in folks with COVID-19.

There has been some hesitancy for vaccine even among doctors and nurses as seen in India. Only 28% of the designated persons appeared to get the vaccine in Punjab Social media has been floating anti-vaccine stories but without any scientific studies. To confirm the effectiveness of a vaccine it has to be seen whether the proper process has been adopted till its final approval. The Oxford-AstraZeneca Covid vaccine trial was voluntarily put on hold at one stage to research why one participant out of many thousands had died. It restarted once it absolutely was clear it absolutely was not associated with the vaccine. Pfizer-BioNTech's vaccine used bits of genetic code to cause an immune reaction and is termed an mRNA vaccine. They claim that it doesn't alter human cells, but merely presents the body with instructions to make immunity to Covid. The Oxford-AstraZeneca vaccine uses a harmless virus altered to seem lots more just like the pandemic virus. Other vaccines sometimes contain other ingredients, like aluminium, that make the vaccine stable or more effective. These experts also claim that these vaccines teach your body's system to recognise and fight the infection they need been designed to safeguard against. Some people do suffer mild symptoms after being vaccinated, like muscle aches or a raised

Corresponding Author: Dalvinder Singh Grewal, Department of Business Executive and Prolific Writer, Desh Bhagagat University, Punjab, India, Tel no: 919815366726; E-mail: dalvinder45@rediffmail.com

Received: May 20, 2021; **Accepted:** June 3, 2021; **Published:** June 10, 2021

Citation: Grewal DS (2021) A View Point on Effectiveness of COVID-19 Vaccines. J Biomed Eng & Med Dev. 6:167.

temperature. this is often not the disease itself, but the body's response to the vaccine.